ReviewJAK-STAT2013
The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis.
Review in JAK-STAT, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 2 syntheses or guidelines pooled it, 315 citations in OpenAlex.
- Pooled it
- The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.European journal of clinical pharmacology · 2022Pooled it
- Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.American journal of clinical dermatology · 2024Trial
- Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2023Trial
- Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.American journal of clinical dermatology · 2021Trial
- Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.Journal of clinical pharmacology · 2021Trial
- Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.JAMA dermatology · 2019Trial
- Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015-2025).Journal of clinical practice and research · 2026Article
- Isolation and Characterization of a Novel Marine Peptide, WPN-15, from Walleye Pollock (Pharmaceutics · 2026Article
- Transcriptomic Effects of Oclacitinib and Prednisolone in an Acute IgE-Mediated Experimental Model of Canine Atopic Dermatitis.Veterinary sciences · 2026Article
- Baricitinib for Itch-Dominant Atopic Dermatitis: A 52-week Baricitinib Real-World Experience in Korea.Annals of dermatology · 2026Article
- Itching, Ionic Channels, Immune System, Magnesium and Antioxidants.Clinical, cosmetic and investigational dermatology · 2026Review
- Genetic analysis of Behçet's disease using whole-exome sequencing and bioinformatics analysis in Korean patients.Frontiers in genetics · 2026Article
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
- Prurigo Nodularis and the Pain Cascade: Understanding the Pathogenesis and Approach to Management.The Journal of clinical and aesthetic dermatology · 2026Review
- Targeting the JAK/STAT pathway in atopic dermatitis.Frontiers in immunology · 2026Review
- In silico modeling guides identification of novel JAK1 variants associated with immune dysregulation.EMBO molecular medicine · 2025Article
- Identifying therapeutic targets for allergic asthma through atopic dermatitis-associated genetic mechanisms.The journal of allergy and clinical immunology. Global · 2025Article
- The role of the skin microbiome in inherited ichthyoses: A systematic review.JAAD international · 2025Review
- Beyond Antihistamines: How Biologic and Small-Molecule Therapies Are Transforming Chronic Spontaneous Urticaria Care in Adults.Clinical drug investigation · 2025Review
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD), a common chronic inflammatory skin disease, is characterized by inflammatory cell skin infiltration. The JAK-STAT pathway has been shown to play an essential role in the dysregulation of immune responses in AD, including the exaggeration of Th2 cell response, the activation of eosinophils, the maturation of B cells, and the suppression of regulatory T cells (Tregs). In addition, the JAK-STAT pathway, activated by IL-4, also plays a critical role in the pathogenesis of AD by upregulating epidermal chemokines, pro-inflammatroy cytokines, and pro-angiogenic factors as well as by downregulating antimicrobial peptides (AMPs) and factors responsible for skin barrier function. In this review, we will highlight the recent advances in our understanding of the JAK-STAT pathway in the pathogenesis of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.